

## 10. Literaturverzeichnis

1. Goerke H. Arzt und Heilkunde. Vom Asklepiospriester zum Klinikarzt. 3000 Jahre Medizin. München: Verlag Georg D.W.Callwey, 1987
2. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland - Häufigkeiten und Trends, 4. erweiterte, aktualisierte Ausgabe ed. Saarbrücken, 2004
3. Ziegler RG, Hoover RN, Pike MC, et al. Migration Pattern and Breast Cancer Risk in Asian-American Women. J Natl Cancer Inst 1993;85:1819-1827
4. Böcker W, Denk H, Heitz PU. Pathologie, 2 ed. München Jena: Urban&Fischer, 2001
5. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. N Engl J Med 2000;342:564-571
6. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-285
7. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 2000;160:953-958
8. Mai KT, Yazdi HM, Burns BF, Perkins DG. Pattern of distribution of intraductal and infiltrating ductal carcinoma: a three-dimensional study using serial coronal giant sections of the breast. Hum Pathol 2000;31:464-474
9. Lagios MD. Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am 1990;70:853-871
10. Winchester DP, Strom EA. Standards for diagnosis and management of ductal carcinoma in situ (DCIS) of the breast. American College of Radiology. American College of Surgeons. College of American Pathologists. Society of Surgical Oncology. CA Cancer J Clin 1998;48:108-128
11. Feig SA. Ductal carcinoma in situ. Implications for screening mammography. Radiol Clin North Am 2000;38:653-668, vii

12. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. *Jama* 1996;275:913-918
13. Bartow SA, Pathak DR, Black WC, Key CR, Teaf SR. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. *Cancer* 1987;60:2751-2760
14. Bhathal PS, Brown RW, Lesueur GC, Russell IS. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. *Br J Cancer* 1985;51:271-278
15. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. *Br J Cancer* 1987;56:814-819
16. Kopans DB, Rafferty E, Georgian-Smith D, et al. A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena. *Cancer* 2003;97:2951-2959
17. Page DL, Dupont WD, L.W. R, al. e. Intraductal carcinoma of the breast: Follow-up after biopsy only. *Cancer* 1982;49:751-758
18. Betsill WL, Rosen PP, Lieberman PH, al. e. Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. *JAMA* 1978;239:1863-1867
19. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. *Cancer* 1995;76:1197-1200
20. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. *Cancer* 1989;63:618-624
21. Solin LJ, Yeh IT, Kurtz J, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment. *Cancer* 1993;71:2532-2542

22. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. *Cancer* 1996;77:2267-2274
23. Goldstein NS, Vicini FA, Kestin LL, Thomas M. Differences in the pathologic features of ductal carcinoma in situ of the breast based on patient age. *Cancer* 2000;88:2553-2560
24. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. *Lancet* 1995;345:1154-1157
25. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. *J Clin Oncol* 1996;14:754-763
26. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. *Lancet* 2000;355:528-533
27. Silverstein MJ, Barth A, Poller DN, et al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. *Eur J Cancer* 1995;31A:1425-1427
28. Silverstein MJ, Lagios MD. Use of predictors of recurrence to plan therapy for DCIS of the breast. *Oncology (Huntingt)* 1997;11:393-406, 409-310; discussion 413-395
29. Sonnenfeld MR, Frenna TH, Weidner N, Meyer JE. Lobular carcinoma in situ: mammographic-pathologic correlation of results of needle-directed biopsy. *Radiology* 1991;181:363-367
30. Liberman L, Sama M, Susnik B, et al. Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings. *AJR Am J Roentgenol* 1999;173:291-299
31. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. *Cancer* 1989;63:181-187
32. Bässler R. Pathologie des Mammakarzinoms. In: Remmele W, ed. *Pathologie*. Berlin, Heidelberg, New York: Springer, 1997:237-339

33. Warwick J, Tabar L, Vitak B, Duffy SW. Time-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish Two-County Study. *Cancer* 2004;100:1331-1336
34. Poggi MM, Danforth DN, Sciuto LC, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. *Cancer* 2003;98:697-702
35. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. *N Engl J Med* 2002;347:1227-1232
36. Lichter AS, Lippman ME, Danforth DN, Jr., et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. *J Clin Oncol* 1992;10:976-983
37. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. *N Engl J Med* 2001;345:1378-1387
38. Sibbering DM, Galea MH, Morgan DA, et al. Safe selection criteria for breast conservation without radical excision in primary operable invasive breast cancer. *Eur J Cancer* 1995;31A:2191-2195
39. Park CC, Mitsumori M, Nixon A, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. *J Clin Oncol* 2000;18:1668-1675
40. Hurd TC, Sneige N, Allen PK, et al. Impact of extensive intraductal component on recurrence and survival in patients with stage I or II breast cancer treated with breast conservation therapy. *Ann Surg Oncol* 1997;4:119-124
41. Tunon-de-Lara C, de-Mascarel I, Mac-Grogan G, et al. Analysis of 676 cases of ductal carcinoma in situ of the breast from 1971 to 1995: diagnosis and treatment--the experience of one institute. *Am J Clin Oncol* 2001;24:531-536

42. Weng EY, Juillard GJ, Parker RG, Chang HR, Gornbein JA. Outcomes and factors impacting local recurrence of ductal carcinoma in situ. *Cancer* 2000;88:1643-1649
43. Schnitt SJ, Abner A, Gelman R, et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. *Cancer* 1994;74:1746-1751
44. Roohan PJ, Bickell NA, Baptiste MS, Therriault GD, Ferrara EP, Siu AL. Hospital volume differences and five-year survival from breast cancer. *Am J Public Health* 1998;88:454-457
45. Gillis CR, Hole DJ. Survival outcome of care by specialist surgeons in breast cancer: a study of 3786 patients in the west of Scotland. *Bmj* 1996;312:145-148
46. Thomson JZ, Evans AJ, Pinder SE, Burrell HC, Wilson AR, Ellis IO. Growth pattern of ductal carcinoma in situ (DCIS): a retrospective analysis based on mammographic findings. *Br J Cancer* 2001;85:225-227
47. Ohtake T, Abe R, Kimijima I, et al. Intraductal extension of primary invasive breast carcinoma treated by breast-conservative surgery. Computer graphic three-dimensional reconstruction of the mammary duct-lobular systems. *Cancer* 1995;76:32-45
48. Kestin LL, Goldstein NS, Lacerna MD, et al. Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy. *Cancer* 2000;88:596-607
49. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. *Cancer* 1995;75:1310-1319
50. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. *N Engl J Med* 1999;340:1455-1461

51. Arnesson LG, Smeds S, Fagerberg G, Grontoft O. Follow-up of two treatment modalities for ductal cancer in situ of the breast. *Br J Surg* 1989;76:672-675
52. Lagios MD, Silverstein MJ. Ductal carcinoma in situ. The success of breast conservation therapy: a shared experience of two single institutional nonrandomized prospective studies. *Surg Oncol Clin N Am* 1997;6:385-392
53. Silverstein MJ, Gierson ED, Colburn WJ, et al. Can intraductal breast carcinoma be excised completely by local excision? Clinical and pathologic predictors. *Cancer* 1994;73:2985-2989
54. Rutgers EJT for the EUSOMA Consensus Group. Quality control in the locoregional treatment of breast cancer. *EJC* 2001;37:447-453
55. Locker AP, Ellis IO, Morgan DA, Elston CW, Mitchell A, Blamey RW. Factors influencing local recurrence after excision and radiotherapy for primary breast cancer. *Br J Surg* 1989;76:890-894
56. Goldstein NS, Kestin L, Vicini F. Intraductal carcinoma of the breast: pathologic features associated with local recurrence in patients treated with breast-conserving therapy. *Am J Surg Pathol* 2000;24:1058-1067
57. Holland R, Hendriks JH, Vebeek AL, Mravunac M, Schuurmans Stekhoven JH. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. *Lancet* 1990;335:519-522
58. Faverly DR, Burgers L, Bult P, Holland R. Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. *Semin Diagn Pathol* 1994;11:193-198
59. van Dongen JA, Fentiman IS, Harris JR, et al. In-situ breast cancer: the EORTC consensus meeting. *Lancet* 1989;2:25-27
60. Claus EB, Chu P, Howe CL, et al. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. *Exp Mol Pathol* 2001;70:303-316
61. Ohtake T, Kimijima I, Fukushima T, et al. Computer-assisted complete three-dimensional reconstruction of the mammary ductal/lobular systems: implications of ductal anastomoses for breast-conserving surgery. *Cancer* 2001;91:2263-2272

62. Winchester DP, Cox JD. Standards for diagnosis and management of invasive breast carcinoma. American College of Radiology. American College of Surgeons. College of American Pathologists. Society of Surgical Oncology. CA Cancer J Clin 1998;48:83-107
63. Heywang-Kobrunner SH, Schreer I. Bildgebende Mammadiagnostik, 2., vollständig überarbeitete und erweiterte Auflage ed. Stuttgart New York: Georg Thieme Verlag, 2003
64. Poplack SP, Tosteson AN, Grove MR, Wells WA, Carney PA. Mammography in 53,803 women from the New Hampshire mammography network. Radiology 2000;217:832-840
65. Kopans DB. The positive predictive value of mammography. AJR Am J Roentgenol 1992;521-526
66. Moskovic E, Sinnott HD, Parsons CA. The accuracy of mammographic diagnosis in surgically occult breast lesions. Clin Radiol 1990;41:344-346
67. Sickles EA. Periodic mammographic follow-up of probably benign lesions: results in 3,184 consecutive cases. Radiology 1991;179:463-468
68. Baker JA, Kornguth PJ, Lo JY, Floyd CE, Jr. Artificial neural network: improving the quality of breast biopsy recommendations. Radiology 1996;198:131-135
69. Hall FM, Storella JM, Silverstone DZ, Wyshak G. Nonpalpable breast lesions: recommendations for biopsy based on suspicion of carcinoma at mammography. Radiology 1988;167:353-358
70. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 1993:1644-1656
71. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355:129-134
72. Olsen O, Gotzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001;358:1340-1342
73. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002;359:909-919

74. International Agency for Research on Cancer (IARC) Working Group. Mammographic Screening. In: IARC Press, 2002
75. de Koning HJ. Mammographic screening: evidence from randomised controlled trials. *Ann Oncol* 2003;14:1185-1189
76. Walter SD. Mammographic screening: case-control studies. *Ann Oncol* 2003;14:1190-1192
77. Hackshaw A. EUSOMA review of mammography screening. *Ann Oncol* 2003;14:1193-1195
78. Duffy SW, Tabar L, Vitak B, et al. The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease. *Eur J Cancer* 2003;39:1755-1760
79. Brown ML, Houn F, Sickles EA, Kessler LG. Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures. *AJR Am J Roentgenol* 1995;165
80. Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. *N Engl J Med* 2003;348:1672-1680
81. Elmore JG, Barton MB, Mocerri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. *N Engl J Med* 1998;338:1089-1096
82. Christiansen CL, Wang F, Barton MB, et al. Predicting the cumulative risk of false-positive mammograms. *J Natl Cancer Inst* 2000;92:1657-1666
83. Fajardo LL, Hillman BJ, Frey C. Correlation between breast parenchymal patterns and mammographer's certainty of diagnosis. *Invest Radiol* 1988;23:505-508
84. Burnett SJ, Ng YY, Perry NM, et al. Benign biopsies in the prevalent round of breast screening: a review of 137 cases. *Clin Radiol* 1995;50:254-258
85. Goldhirsch A, Colleoni M, Domenighetti G, Gelber RD. Systemic treatments for women with breast cancer: outcome with relation to screening for the disease. *Ann Oncol* 2003;14:1212-1214
86. Potterton AJ, Peakman DH, Young IR. Ultrasound demonstration of small breast cancers detected by mammographic screening. *Clin Radiol* 1994;49:808



87. Soo MS, Baker JA, Rosen EL. Sonographic detection and sonographically guided biopsy of breast microcalcifications. *AJR Am J Roentgenol* 2003;180:941-948
88. Yang WT, Tse GMK. Sonographic, mammographic, and histopathologic correlation of symptomatic ductal carcinoma in situ. *AJR Am J Roentgenol* 2004;182:101-110
89. Liberman L, Morris EA, Benton CL, Abramson AF, Dershaw DD. Probably benign lesions at breast magnetic resonance imaging: preliminary experience in high-risk women. *Cancer* 2003;98:377-388
90. Orel SG, Reynolds C, Schnall MD, Solin LJ, Fraker DL, Sullivan DC. Breast carcinoma: MR imaging before re-excisional biopsy. *Radiology* 1997;205:429-436
91. Soderstrom CE, Harms SE, Copit DS, et al. Three-dimensional RODEO breast MR imaging of lesions containing ductal carcinoma in situ. *Radiology* 1996;201:427-432
92. Soderstrom CE, Harms SE, Farrell RS, Jr., Pruneda JM, Flamig DP. Detection with MR imaging of residual tumor in the breast soon after surgery. *AJR Am J Roentgenol* 1997;168:485-488
93. Nakahara H, Namba K, Wakamatsu H, et al. Extension of breast cancer: comparison of CT and MRI. *Radiat Med* 2002;20:17-23
94. Nakahara H, Namba K, Fukami A, et al. Three-dimensional MR imaging of mammographically detected suspicious microcalcifications. *Breast Cancer* 2001;8:116-124
95. Orel SG. High-resolution MR imaging for the detection, diagnosis, and staging of breast cancer. *Radiographics* 1998;18:903-912
96. Heywang-Kobrunner SH, Viehweg P, Heinig A, Kuchler C. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. *Eur J Radiol* 1997;24:94-108
97. Orel SG, Mendonca MH, Reynolds C, Schnall MD, Solin LJ, Sullivan DC. MR imaging of ductal carcinoma in situ. *Radiology* 1997;202:413-420

98. Sittek H, Kessler M, Heuck AF, et al. [Morphology and contrast enhancement of ductal carcinoma in situ in dynamic 1.0 T MR mammography]. *Rofo* 1997;167:247-251
99. ACR. Breast Imaging Reporting and Data System Atlas (BI-RADS Atlas). In: Reston, VA: American College of Radiology, 2003
100. Orel SG, Kay N, Reynolds C, Sullivan DC. BI-RADS categorization as a predictor of malignancy. *Radiology* 1999;211:845-850
101. Liberman L, Abramson AF, Squires FB, Glassman JR, Morris EA, Dershaw DD. The breast imaging reporting and data system: positive predictive value of mammographic features and final assessment categories. *AJR Am J Roentgenol* 1998;171:35-40
102. Cyrllak D. Induced costs of low-cost screening mammography. *Radiology* 1988;168:661-663
103. Newman MR, Frost FA, Sterrett GF, et al. Diagnosis of breast microcalcifications: a comparison of stereotactic FNA and core imprint cytology as adjuncts to core biopsy. *Pathology* 2001;33:449-453
104. Pisano ED, Fajardo LL, Tsimikas J, et al. Rate of insufficient samples for fine-needle aspiration for nonpalpable breast lesions in a multicenter clinical trial: The Radiologic Diagnostic Oncology Group 5 Study. The RDOG5 investigators. *Cancer* 1998;82:679-688
105. Andreu FJ, Sentis M, Castaner E, et al. The impact of stereotactic large-core needle biopsy in the treatment of patients with nonpalpable breast lesions: a study of diagnostic accuracy in 510 consecutive cases. *Eur Radiol* 1998;8:1468-1474
106. Hagedorn K, Kramer S, Mitze M, et al. [Interventional methods in breast diagnosis. Histological vs. cytological evaluation of core cut biopsies of the breast]. *Aktuelle Radiol* 1998;8:278-282
107. Kopans DB. Review of stereotactic large-core needle biopsy and surgical biopsy results in nonpalpable breast lesions. *Radiology* 1993:665-666
108. Parker SH, Burbank F, Jackman RJ, et al. Percutaneous large-core breast biopsy: a multi-institutional study. *Radiology* 1994;193:359-364

109. Verkooijen HM. Diagnostic accuracy of stereotactic large-core needle biopsy for nonpalpable breast disease: results of a multicenter prospective study with 95% surgical confirmation. *Int J Cancer* 2002;99:853-859
110. Britton PD, Flower CD, Freeman AH, et al. Changing to core biopsy in an NHS breast screening unit. *Clin Radiol* 1997;52:764-767
111. Schulz-Wendtland R, Kramer S, Lang N, Bautz W. Ultrasonic guided microbiopsy in mammary diagnosis: indications, technique and results. *Anticancer Res* 1998;18:2145-2146
112. Brenner RJ, Fajardo L, Fisher PR, et al. Percutaneous core biopsy of the breast: effect of operator experience and number of samples on diagnostic accuracy. *AJR Am J Roentgenol* 1996:341-346
113. Lee CH, Philpotts LE, Horvath LJ, Tocino I. Follow-up of breast lesions diagnosed as benign with stereotactic core-needle biopsy: frequency of mammographic change and false-negative rate. *Radiology* 1999;212:189-194
114. Jackman RJ, Nowels KW, Rodriguez-Soto J, Marzoni FA, Jr., Finkelstein SI, Shepard MJ. Stereotactic, automated, large-core needle biopsy of nonpalpable breast lesions: false-negative and histologic underestimation rates after long-term follow-up. *Radiology* 1999;210:799-805
115. Liberman L, Dershaw DD, Glassman JR, et al. Analysis of cancers not diagnosed at stereotactic core breast biopsy. *Radiology* 1997;203:151-157
116. Parker SH, Klaus AJ. Performing a breast biopsy with a directional, vacuum-assisted biopsy instrument. *Radiographics* 1997;17:1233-1252
117. Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with directional, vacuum-assisted biopsy. *Radiology* 1997;202:843-847
118. Burbank F, Parker SH, T.J. F. Stereotactic breast biopsy: improved tissue harvesting with the Mammotome. *Am Surg* 1996:738-744
119. Meyer JE, Smith DN, DiPiro PJ, et al. Stereotactic breast biopsy of clustered microcalcifications with a directional, vacuum-assisted device. *Radiology* 1997;204:575-576

120. Dahlstrom JE, Jain S. Histological correlation of mammographically detected microcalcifications in stereotactic core biopsies. *Pathology* 2001;33:444-448
121. Bagnall MJ, Evans AJ, Wilson AR, Burrell H, Pinder SE, Ellis IO. When have mammographic calcifications been adequately sampled at needle core biopsy? *Clin Radiol* 2000;55:548-553
122. Liberman L, Smolkin JH, Dershaw DD, Morris EA, Abramson AF, Rosen PP. Calcification retrieval at stereotactic, 11-gauge, directional, vacuum-assisted breast biopsy. *Radiology* 1998;208:251-260
123. Darling ML, Smith DN, Lester SC, et al. Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: results of surgical excision. *AJR Am J Roentgenol* 2000;175:1341-1346
124. Won B, Reynolds HE, Lazaridis CL, Jackson VP. Stereotactic biopsy of ductal carcinoma in situ of the breast using an 11-gauge vacuum-assisted device: persistent underestimation of disease. *AJR Am J Roentgenol* 1999;173:227-229
125. Liberman L, Cohen MA, Dershaw DD, Abramson AF, Hann LE, Rosen PP. Atypical ductal hyperplasia diagnosed at stereotaxic core biopsy of breast lesions: an indication for surgical biopsy. *AJR Am J Roentgenol* 1995;164:1111-1113
126. Jackman RJ, Burbank F, Parker SH, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. *Radiology* 2001;218:497-502
127. Philpotts LE, Shaheen NA, Carter D, Lange RC, Lee CH. Comparison of rebiopsy rates after stereotactic core needle biopsy of the breast with 11-gauge vacuum suction probe versus 14-gauge needle and automatic gun. *AJR Am J Roentgenol* 1999;172:683-687
128. Stomper PC, Margolin FR. Ductal carcinoma in situ: the mammographer's perspective. *AJR Am J Roentgenol* 1994;162:585-591
129. Holland R, Hendriks JH. Microcalcifications associated with ductal carcinoma in situ: mammographic-pathologic correlation. *Semin Diagn Pathol* 1994;11:181-192

130. Winchester DP, Jeske JM, Goldschmidt RA. The diagnosis and management of ductal carcinoma in-situ of the breast. *CA Cancer J Clin* 2000;50:184-200
131. Hall FM. Mammography in the diagnosis of in situ breast carcinoma. *Radiology* 1988;168:279-280
132. Berg WA, Campassi C, Langenberg P, Sexton MJ. Breast Imaging Reporting and Data System: inter- and intraobserver variability in feature analysis and final assessment. *AJR Am J Roentgenol* 2000;174:1769-1777
133. Bodai BI, Boyd B, Brown L, Wadley H, Zannis VJ, Holzman M. Total cost comparison of 2 biopsy methods for nonpalpable breast lesions. *Am J Manag Care* 2001;7:527-538
134. Wallace JE, Sayler C, McDowell NG, Moseley HS. The role of stereotactic biopsy in assessment of nonpalpable breast lesions. *Am J Surg* 1996;171:471-473
135. Gundry KR, Berg WA. Treatment issues and core needle breast biopsy: clinical context. *AJR Am J Roentgenol* 1998;171:41-49
136. Schulz K-D, Albert U-S. Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland: W.Zuckschwerdt Verlag München Wien New York, 2003
137. Schulz-Wendtland R, Heywang-Kobrunner SH, Aichinger U, Kramer S, Wenkel E, Bautz W. [Do tissue marker clips after sonographically or stereotactically guided breast biopsy improve follow-up of small breast lesions and localisation of breast cancer after chemotherapy?]. *Rofo* 2002;174:620-624
138. Heywang-Kobrunner SH, Schreer I, Decker T, Böcker W. Interdisciplinary consensus on the use and technique of vacuum assisted stereotactic breast biopsy. *Eur J Radiol* 2003;47:232-236
139. EUSOMA. The requirements of a specialist breast unit. *Eur J Cancer* 2000;36:2288-2293
140. Perry NM on behalf of The EUSOMA Working Party. Quality assurance in the diagnosis of breast disease. *EJC* 2001;37:159-172
141. Rissanen TJ, Makarainen HP, Mattila SI, et al. Wire localized biopsy of breast lesions: a review of 425 cases found in screening or clinical mammography. *Clin Radiol* 1993;47:14-22

142. Jackman RJ, Marzoni FA, Jr. Needle-localized breast biopsy: why do we fail? *Radiology* 1997;204:677-684
143. Verkooijen HM, Borel Rinkes IH, Peeters PH, et al. Impact of stereotactic large-core needle biopsy on diagnosis and surgical treatment of nonpalpable breast cancer. *Eur J Surg Oncol* 2001;27:244-249
144. Lee CH, Egglin TK, Philpotts L, Mainiero MB, Tocino I. Cost-effectiveness of stereotactic core needle biopsy: analysis by means of mammographic findings. *Radiology* 1997;202:849-854
145. Yim JH, Barton P, Weber B, et al. Mammographically detected breast cancer. Benefits of stereotactic core versus wire localization biopsy. *Ann Surg* 1996;223:688-697; discussion 697-700
146. Liberman L, Gougoutas CA, Zakowski MF, et al. Calcifications highly suggestive of malignancy: comparison of breast biopsy methods. *AJR Am J Roentgenol* 2001;177:165-172
147. Vargas HI, Agbunag RV, Khaikhali I. State of the art of minimally invasive breast biopsy: principles and practice. *Breast Cancer* 2000;7:370-379
148. Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. *Cancer* 1996;78:1403-1416
149. Stomper PC, Connolly JL, Meyer JE, Harris JR. Clinically occult ductal carcinoma in situ detected with mammography: analysis of 100 cases with radiologic-pathologic correlation. *Radiology* 1989;172:235-241
150. Mokbel K, Choy C, Leris C, et al. Predictors of positive margins after local excision of ductal carcinoma in situ. *Am J Surg* 2001;181:91-95
151. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. *J Clin Oncol* 1998;16:441-452
152. Skinner KA, Helsper JT, Deapen D, Ye W, Sposto R. Breast cancer: do specialists make a difference? *Ann Surg Oncol* 2003;10:606-615
153. Jackman RJ, Marzoni FA, Jr., Nowels KW. Percutaneous removal of benign mammographic lesions: comparison of automated large-core and directional

- vacuum-assisted stereotactic biopsy techniques. *AJR Am J Roentgenol* 1998;171:1325-1330
154. Liberman L, Drotman M, Morris EA, et al. Imaging-histologic discordance at percutaneous breast biopsy. *Cancer* 2000;89:2538-2546
  155. Siegmann KC, Wersebe A, Fischmann A, et al. [Stereotactic vacuum-assisted breast biopsy--success, histologic accuracy, patient acceptance and optimizing the BI-RADSTM-correlated indication]. *Rofo* 2003;175:99-104
  156. Brem RF, Schoonjans JM, Sanow L, Gatewood OM. Reliability of histologic diagnosis of breast cancer with stereotactic vacuum-assisted biopsy. *Am Surg* 2001;67:388-392
  157. Rao A, Parker S, Ratzer E, Stephens J, Fenoglio M. Atypical ductal hyperplasia of the breast diagnosed by 11-gauge directional vacuum-assisted biopsy. *Am J Surg* 2002;184:534-537
  158. Jackman RJ, Birdwell RL, Ikeda DM. Atypical ductal hyperplasia: can some lesions be defined as probably benign after stereotactic 11-gauge vacuum-assisted biopsy, eliminating the recommendation for surgical excision? *Radiology* 2002;224:548-554
  159. Philpotts LE, Lee CH, Horvath LJ, Lange RC, Carter D, Tocino I. Underestimation of breast cancer with 11-gauge vacuum suction biopsy. *AJR Am J Roentgenol* 2000;175:1047-1050
  160. Kettritz U, Rotter K, Schreer I, et al. Stereotactic vacuum-assisted breast biopsy in 2874 patients. *Cancer* 2004;100:245-251
  161. Maganini RO, Klem DA, Huston BJ, Bruner ES, Jacobs HK. Upgrade rate of core biopsy-determined atypical ductal hyperplasia by open excisional biopsy. *Am J Surg* 2001;182:355-358
  162. Brem RF, Behrndt VS, Sanow L, Gatewood OM. Atypical ductal hyperplasia: histologic underestimation of carcinoma in tissue harvested from palpable breast lesions using 11-gauge stereotactically guided directional vacuum-assisted biopsy. *AJR Am J Roentgenol* 1999;172:1405-1407
  163. Liberman L, LaTrenta LR, Dershaw DD, et al. Impact of core biopsy on the surgical management of palpable breast cancer. *AJR Am J Roentgenol* 1997;168:495-499

164. Fondrinier E, Lorimier G, Guerin-Boblet V, Bertrand AF, Mayras C, Dauver N. Breast microcalcifications: multivariate analysis of radiologic and clinical factors for carcinoma. *World J Surg* 2002;26:290-296
165. Lacquement MA, Mitchell D, Hollingsworth AB. Positive predictive value of the Breast Imaging Reporting and Data System. *J Am Coll Surg* 1999;189:34-40
166. Bilgen IG, Ustun EE, Memis A. Fat necrosis of the breast: clinical, mammographic and sonographic features. *Eur J Radiol* 2001;39:92-99
167. Evans A, Pinder S, Wilson R, et al. Ductal carcinoma in situ of the breast: correlation between mammographic and pathologic findings. *AJR Am J Roentgenol* 1994;162:1307-1311
168. Foschini MP, Fornelli A, Peterse JL, Mignani S, Eusebi V. Microcalcifications in ductal carcinoma in situ of the breast: histochemical and immunohistochemical study. *Hum Pathol* 1996;27:178-183
169. Lanyi M. Pattern analysis of 5641 microcalcifications in 100 mamma duct carcinomas: polymorphism. *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr* 1983;139:240-248
170. de Lafontan B, Daures JP, Salicru B, et al. Isolated clustered microcalcifications: diagnostic value of mammography - series of 400 cases with surgical verification. *Radiology* 1994;190:479-483
171. Dinkel HP, Gassel AM, Tschammler A. Is the appearance of microcalcifications on mammography useful in predicting histological grade of malignancy in ductal cancer in situ? *Br J Radiol* 2000;73:938-944
172. Slanetz PJ, Giardino AA, Oyama T, et al. Mammographic appearance of ductal carcinoma in situ does not reliably predict histologic subtype. *Breast J* 2001;7:417-421
173. Evans AJ, Wilson AR, Burrell HC, Ellis IO, Pinder SE. Mammographic features of ductal carcinoma in situ (DCIS) present on previous mammography. *Clin Radiol* 1999;54:644-646
174. Sickles EA. Management of probably benign breast lesions. *Radiol Clin North Am* 1995;33:1123-1130



175. Ancona A, Caiffa L, Fazio V. [Digital stereotactic breast microbiopsy with the mammotome: study of 122 cases]. *Radiol Med (Torino)* 2001;101:341-347
176. Burak WE, Jr., Owens KE, Tighe MB, et al. Vacuum-assisted stereotactic breast biopsy: histologic underestimation of malignant lesions. *Arch Surg* 2000;135:700-703
177. Lai JT, Burrowes P, MacGregor JH. Diagnostic accuracy of a stereotaxically guided vacuum-assisted large-core breast biopsy program in Canada. *Can Assoc Radiol J* 2001;52:223-227
178. Harvey JM, Sterrett GF, Frost FA. Atypical ductal hyperplasia and atypia of uncertain significance in core biopsies from mammographically detected lesions: correlation with excision diagnosis. *Pathology* 2002;34:410-416
179. Jackman RJ, Burbank F, Parker SH, et al. Atypical ductal hyperplasia diagnosed at stereotactic breast biopsy: improved reliability with 14-gauge, directional, vacuum-assisted biopsy. *Radiology* 1997;204:485-488

## **EIDESSTATTLICHE VERSICHERUNG**

gemäß Habilitationsordnung der Medizinischen Fakultät Charité

Hiermit erkläre ich, dass

- keine staatsanwaltschaftlichen Ermittlungsverfahren gegen mich anhängig sind,
- weder früher noch gleichzeitig ein Habilitationsverfahren durchgeführt oder angemeldet wurde
- die vorgelegte Habilitationsschrift ohne fremde Hilfe verfasst, die beschriebenen Ergebnisse selbst gewonnen wurden, sowie die verwendeten Hilfsmittel, die Zusammenarbeit mit anderen Wissenschaftlerinnen oder Wissenschaftlern und technischen Hilfskräften und die Literatur vollständig angegeben sind,
- mir die geltende Habilitationsordnung bekannt ist.

Berlin, den 10.11.2004

Dr. Ute Kettritz